For antibodies produced in mammalian cell lines such as Chinese Hamster Ovary (CHO) cells, viral contamination constitutes a potential safety risk. Characterizing the viral clearance and inactivation capacity of the manufacturing process mitigates the risk of iatrogenic transmission of pathogenic viruses and substantially enhances product safety, which is critical for the safety of biotherapeutic products. Prior to clinical trial initiation and commercial licensing of biological products, it is mandatory to demonstrate that the manufacturing process is capable of clearing both known and adventitious viruses.
1 Regulatory Guidelines for Viral Clearance and Inactivation Validation at Home and Abroad
Major global regulatory authorities have established stringent and mature regulatory frameworks governing viral safety of biopharmaceuticals and biological products.
1999: ICH Q5A (R1): Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin
1999: ICH Q5D: Derivation and Characterization of Cell Substrates Used for Production of Biotechnological/Biological Products
1985: FDA Points to Consider in the Production and Testing of New Drug and Biologicals Produced by Recombinant DNA Technology
1984: FDA Points to Consider in the Characterization of Cell Lines Seed to Produce Biological Products
1993: FDA Points to Consider in the Characterization of Cell Lines Used to Produce Biologicals
1997: FDA Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use
2016: USP General Chapter <1050>: Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin
2016: USP General Chapter <1051>: Design, Evaluation, and Characterization of Viral Clearance Procedures
2008: EMA/CHMP/BWP/532517/2008 Guideline on Development, Production, Characterisation and Specification for Monoclonal Antibodies and Related Products
2006: EMEA/CHMP/BWP/398498/2005 Guideline on Viral Safety Evaluation of Biotechnological Investigational Medicinal Products
1996: CPMP/BWP/268/95 Note for Guidance on Viral Validation Studies: The Design, Contribution and Interpretation of Studies Validating the Inactivation and Removal of Viruses
2002: CDE Technical Guidelines for Viral Removal/Inactivation Methods and Validation of Blood Products
2005: CDE General Technical Review Principles for Viral Safety Evaluation of Biological Products Derived from Tissue Extraction and Eukaryotic Cell Expression
2002: CFDA Announcement on Further Strengthening Supervision and Administration of Bovine-derived and Related Pharmaceutical Products
2003: CDE Technical Guidelines for Production and Quality Control of Bovine Serum for Cell Culture
2003: CDE Technical Guidelines for Live Vaccine Products Using Viral Vectors for Prophylactic Use
2003: CDE General Technical Review Principles for Cell Substrates Used in Vaccine Production
2005: CDE Technical Guidelines for Quality Control of Human Monoclonal Antibodies
2003: CDE Technical Guidelines for Quality Control of Human Recombinant DNA Products
2020: Chinese Pharmacopoeia Commission, Chinese Pharmacopoeia Volume III 2020 Edition: General Principles for Biological Products; Quality Control of Raw Materials and Excipients for Biological Production; Management and Quality Control of Seed Lots for Production and Testing of Biological Products; Preparation and Quality Control of Animal Cell Substrates for Production and Testing of Biological Products; Human Plasma for Blood Product Production; Viral Safety Control of Biological Products
2020: Chinese Pharmacopoeia Commission, Chinese Pharmacopoeia Volume III 2020 Edition: General Principles and Guidelines – Microbiological Examination: General Chapter 3302 Adventitious Viral Agent Assay; General Chapter 3303 Murine Virus Assay; General Chapter 3306 Technical Requirements for Viral Nucleic Acid Detection of Human Plasma for Blood Product Production; General Chapter 3308 Avian Viral Fluorescent Quantitative PCR (Q-PCR) Assay
2020: Chinese Pharmacopoeia Commission, Chinese Pharmacopoeia Volume III 2020 Edition: General Principles and Guidelines – Specific Biological Raw Materials/Animals and Excipients: General Chapter 3601 Quality Control of Laboratory Animals for Production and Testing of Biological Products; General Chapter 3604 Newborn Calf Serum
Domestic guidelines for viral safety are consistent with international guiding principles aligned with ICH Q5A standards adopted by the US and EU authorities. Viral safety control of biological products is implemented primarily through three core strategies:
Ensure viral freedom of all raw materials used for product manufacturing;
Perform viral testing at the end of cell culture to confirm the absence of viral contamination during cultivation;
Conduct viral clearance validation to verify that the purification process can eliminate known viruses and adventitious viruses undetectable by routine viral assays.
Chinese Hamster Ovary (CHO) cells are one of the dominant host cell platforms for the production of antibody-based biologicals. CHO cells inherently produce endogenous retrovirus-like particles (RVLPs), with titers ranging from \(10^3\) to \(10^9\) particles per milliliter detected in cell culture supernatant. These particles share high similarity with infectious retroviruses in morphology, biochemical properties and genetic sequences. The viral inactivation and removal capacity serves as a key indicator for evaluating the robustness and qualification of antibody downstream manufacturing processes.
Guidelines from ICH, FDA and CDE mandate viral clearance validation for downstream processes, requiring the inclusion of two mechanistically complementary and effective viral inactivation/removal unit operations in the downstream workflow. Domestically, completion of viral clearance validation for critical process steps is generally required prior to clinical trial authorization, while full-process viral clearance validation incorporating chromatographic resin lifespan assessment is mandatory at the commercial licensing stage.
2 Viral Safety Assessment for Antibody Products
Viral clearance capacity is evaluated via spiking studies: live infectious indicator viruses with defined titers are spiked into raw materials or process intermediates at designated production stages. Samples are processed under scaled-down manufacturing conditions mimicking commercial production parameters, and residual viral titers are quantified post-treatment. Viral clearance performance is assessed by calculating the Log Reduction Value (LRV).
A process step with LRV ≥ 4 log₁₀ is defined as an effective viral clearance step. Steps with LRV ＜ 4 log₁₀ are considered contributory to overall process viral clearance. Due to inherent limitations of viral validation, steps with LRV ≤ 1 log₁₀ make negligible contribution to viral mitigation and are excluded from total process LRV summation.
When adopting scaled-down process models for viral validation, study designs shall be scientifically rational and fully representative of commercial manufacturing. Process parameters in scaled-down models must strictly match those of full-scale production, especially for unit operations with proven viral clearance efficacy.
3 Common Indicator Viruses and Validation Design
ICH Q5A mandates the use of no fewer than 3 indicator viruses for viral clearance validation, while a panel of 4 viruses is conventionally adopted in routine practice. X-MuLV, PRV, Reo-3 and MVM are the most widely applied indicator viruses for viral clearance validation in CHO-based manufacturing platforms.
Retroviruses and herpesviruses are enveloped viruses characterized by large particle size and low physicochemical stability. Reoviruses and parvoviruses are non-enveloped viruses with small particle size and high physicochemical resistance. Murine leukemia virus is the most representative retrovirus, while minute virus of mice (MVM) is the standard model parvovirus. X-MuLV is selected to mimic endogenous retrovirus-like particles derived from host CHO cells. MVM can infect mainstream antibody production cell lines; its small particle size and high physicochemical resistance make it an ideal model for recalcitrant adventitious viruses that are difficult to remove.
4 Viral Clearance and Inactivation Unit Operations in Downstream Processing
Major downstream unit operations with viral inactivation or removal capability include solvent/detergent (S/D) treatment, low-pH incubation, chromatographic purification (Protein A affinity chromatography, cation/anion exchange chromatography, hydrophobic interaction chromatography, mixed-mode chromatography) and viral nanofiltration.
4.1 Solvent/Detergent (S/D) Viral Inactivation
Non-ionic detergents such as Polysorbate 80 and Triton X-100 (as well as Triton X-45) combined with tributyl phosphate (organic solvent) effectively disrupt the lipid envelope of enveloped viruses. Stripping of lipid membranes abolishes viral adhesion and infectivity, with minimal impact on antibody structural integrity. S/D treatment is exclusively effective against enveloped viruses and exhibits no inactivation efficacy toward non-enveloped viruses.
Prior to S/D spiking, feedstock shall be pre-filtered through 0.45 μm or finer filters to remove particulate contaminants, which may shield embedded viruses and compromise inactivation efficiency. Complete homogenization is required after S/D addition. If filtration is performed post S/D dosing, residual S/D concentration must remain within the effective working range. The entire inactivation process requires strict temperature control and gentle continuous stirring to ensure homogeneous S/D distribution and temperature uniformity throughout the bulk solution.
S/D reagents can be used alone or in combination; critical process parameters include incubation temperature and hold time. Impacts of S/D addition on product stability, quality and residual levels must be fully evaluated. S/D inactivation is typically implemented at the early downstream stage, immediately after cell culture harvest clarification and prior to Protein A affinity chromatography, enabling subsequent purification steps to remove residual S/D efficiently.
4.2 Low-pH Incubation for Viral Inactivation
Low-pH incubation induces denaturation of the envelope and capsid proteins of enveloped viruses, blocking viral binding to cellular receptors and eliminating infectivity, whereas it shows marginal efficacy against non-enveloped viruses such as MVM. The low-pH viral inactivation step is conventionally positioned immediately after Protein A low-pH elution. Citric acid-based buffers are commonly used to adjust the eluate to target pH for controlled incubation, followed by pH neutralization with Tris buffer prior to depth filtration and subsequent processing.
Key influencing parameters include pH value, incubation duration, temperature and buffer composition. The worst-case conditions for low-pH viral inactivation are marginal high pH, low temperature, short hold time and low ionic strength. Inactivation efficacy increases with elevated temperature and decreases with rising pH, typically achieving 5–6 log₁₀ viral reduction. X-MuLV undergoes rapid inactivation at pH 3.6 with minimal interference from other parameters; inactivation efficacy is significantly compromised at pH 3.7 and 3.8. Supplemental arginine in process intermediates can enhance viral inactivation, yielding robust efficacy even at pH 4.0.
Beyond enveloped viral inactivation, pH neutralization post incubation facilitates precipitation and removal of host cell proteins (HCPs) and residual DNA. However, low-pH conditions may induce antibody aggregation, fragmentation and deamidation. Process pH and hold time must be optimized via experimental characterization of antibody pH tolerance to balance viral inactivation performance and product quality attributes.
4.3 Chromatographic Viral Clearance
Chromatography separates target antibodies from impurities and viral contaminants based on differences in physicochemical properties, serving as a core viral clearance modality. Common formats include Protein A affinity chromatography, ion exchange chromatography, hydrophobic interaction chromatography and mixed-mode chromatography.
4.3.1 Protein A Affinity Chromatography
Viral clearance by Protein A chromatography is primarily achieved via flow-through exclusion: viruses co-elute with non-target impurities during sample loading, and clearance performance is largely independent of resin lifespan. Despite high selectivity toward monoclonal antibodies (mAbs), Protein A generally delivers moderate viral clearance, with average LRVs of 2.98 for X-MuLV and 2.32 for MVM. LRV values vary substantially across individual mAb products, ranging from 1 log to 6 log, yet demonstrate high reproducibility for a defined product and process.
Studies have shown that typical process parameters including loading capacity, flow rate, wash buffer molarity, elution pH and fraction collection criteria exert minimal impact on viral clearance. A positive correlation exists between X-MuLV and MVM clearance for specific product-process combinations. Variable viral clearance across products is primarily attributed to non-specific binding between viruses and mAbs leading to co-elution. Modifying wash buffers with dissociation additives effectively improves viral clearance, analogous to HCP removal optimization. Standard Protein A workflows incorporate post-load washing with 250–500 mM NaCl; increasing salt concentration up to 1 M yields only marginal LRV improvement, indicating viral-mAb interactions are mediated not only by electrostatic forces but also by hydrophobic interactions and hydrogen bonding. Wash buffers supplemented with 3 M urea achieve more pronounced enhancement, and combined use of multiple additives is recommended for optimal performance.
4.3.2 Anion Exchange Chromatography (AEX)
AEX is typically operated in flow-through mode for viral clearance. Most mAbs possess an isoelectric point (pI) higher than conventional indicator viruses; optimized buffer conditions allow mAb flow-through while low-pI viruses bind electrostatically to anion exchange resins. Flow-through AEX delivers robust clearance for both enveloped and non-enveloped viruses, with average LRVs of 4.22 for X-MuLV and 3.25 for MVM.
Viral-AEX binding is dominated by electrostatic interactions, with higher LRV achieved under low-salt conditions. X-MuLV clearance remains stable across pH 5.0–8.0 irrespective of pH variation. Although X-MuLV has a theoretical pI of 5.8, it binds to AEX resins at pH 5.0, contrary to conventional electrostatic prediction, indicating persistent negatively charged domains on the viral surface. In contrast, MVM LRV increases with elevated pH and exhibits suboptimal clearance under conditions below its pI.
Viral surface charge distribution, rather than bulk pI, is the dominant determinant of viral-ion exchange resin interaction. Even low-pI mAbs can flow through AEX resins when operated above their pI. Recommended operating windows for robust AEX viral clearance: pH 7.0–8.5, conductivity ＜ 14 mS/cm, and resin loading capacity ＜ 100 mg/mL. Weak-binding mode AEX maintains potent viral clearance even for feedstocks with high aggregate levels, concurrent with improved removal of DNA, HCPs and antibody aggregates. Low LRV observed for certain mAbs is attributed to viral-mAb electrostatic complexation, which masks viral surface charge and results in co-flow-through. Positively charged AEX resins compete with mAbs for viral binding, mitigating the impact of viral-mAb interaction relative to Protein A chromatography.
4.3.3 Cation Exchange Chromatography (CEX)
CEX is widely applied in polishing workflows, typically operated in bind-elute mode with viral elution modulated by linear or gradient salt elevation. CEX efficiently removes X-MuLV, PRV and Reo-3 but exhibits poor efficacy against MVM. Operating pH is the critical parameter governing X-MuLV clearance: consistent LRV ≥ 4.0 is achieved at pH 5.0, while clearance declines sharply at pH 5.5/6.0 and diminishes completely at pH 6.5. MVM clearance remains consistently suboptimal (LRV ＜ 2.0) across all tested pH conditions.
For resins such as Fractogel SO3, pH 5.0 represents the optimal operational window for selective separation of 6.8–9.0 pI mAbs and X-MuLV. At pH 5.0, no residual virus is detected in eluted product with LRV ≥ 4.4; at pH 6.5, virus and mAb co-elute with LRV reduced to 1.4, confirming viral clearance is achieved via resin retention rather than inactivation. Electrostatic interactions dominate viral-CEX binding. X-MuLV envelopes contain clustered charged domains enabling strong resin association at pH 5.0, which are absent in MVM. This pH condition enhances viral-resin binding and disrupts viral-mAb complexation to further favor viral removal.
When deployed as a capture step instead of Protein A, CEX delivers inferior viral clearance under comparable pH (5.0–5.7) and conductivity (3.0–6.0 mS/cm) conditions, though optimized parameters can match Protein A performance. HCP load in feedstock exerts minimal impact on polishing-stage CEX viral clearance; however, high HCP levels in harvest feedstock compete for resin binding and reduce clearance efficiency when CEX is used for capture. Overload-mode CEX (up to 10× dynamic binding capacity) using resins such as POROS XS achieves effective clearance across all four indicator viruses. Elevated flow rate reduces LRV, while overload-mode performance is comparable to conventional bind-elute workflows.
4.3.4 Hydrophobic Interaction Chromatography (HIC)
HIC separates molecules based on surface hydrophobicity and serves as an alternative polishing modality, operable in both bind-elute and flow-through modes. Viral clearance is mediated by viral adsorption to HIC resins under optimized conditions. Critical performance parameters include resin loading capacity, pH, linear velocity and conductivity. High loading, elevated pH, high flow rate and low conductivity represent worst-case conditions for viral clearance. Resins with stronger hydrophobicity yield superior viral clearance but compromise product yield, requiring balanced optimization. Viral clearance efficacy varies by virus type due to differences in surface hydrophobicity. Evaluation of POROS Ethyl, POROS Benzyl and POROS Benzyl Ultra resins demonstrates complete X-MuLV clearance across all formats, while partial MVM removal is limited by the low surface hydrophobicity of MVM particles.
4.3.5 Mixed-Mode Chromatography
Mixed-mode resins integrate ionic and hydrophobic functional groups, with binding governed by synergistic electrostatic and hydrophobic interactions rather than simple additive effects. They deliver high and robust viral clearance over broader pH and conductivity ranges compared to single-mode resins. Capto Adhere, a mainstream mixed-mode resin, mediates ionic, hydrophobic and hydrogen-bonding interactions; flow-through operation at pH 4.5–6.5 and conductivity 10–30 mS/cm achieves effective X-MuLV and MVM clearance.
Hydroxyapatite (HA) is a unique mixed-mode resin combining cation exchange and metal affinity interactions. At pH 6.7–7.8, HA chromatography yields consistent X-MuLV (＞4 log) and PRV (3–4 log) clearance across multiple mAbs, while SV40 clearance varies widely from 1 log to 4 log. Viral clearance occurs via resin binding during loading and elution, with viral-mAb interactions modulating retention performance. Supplemental PEG enhances HA viral clearance analogous to aggregate removal optimization. Orthogonality of mixed-mode versus single-mode chromatographic steps for viral clearance is case-dependent. For instance, POROS HQ (AEX) and Capto Adhere exhibit equivalent X-MuLV clearance, while Capto Adhere delivers substantially higher MVM LRV.
4.4 Viral Nanofiltration
Viral nanofiltration is regarded as the most robust and reliable viral clearance technology, operating on a size-exclusion mechanism. Antibody molecules pass through membrane pores while larger viral particles are retained, achieving effective removal of both enveloped and non-enveloped viruses with typical LRV ≥ 4 log₁₀ and no detrimental impact on product quality. Membrane pore size is selected based on target protein molecular dimensions: ~20 nm parvovirus-grade membranes are designed for small non-enveloped virus removal, while 35–50 nm retrovirus-grade membranes target larger enveloped viruses. Parvovirus-grade membranes have become indispensable due to the limited efficacy of low-pH incubation against small non-enveloped viruses.
Post-filtration integrity testing is mandatory for viral filters, which are conventionally positioned at the final polishing stage of downstream workflows. Key influencing parameters include feedstock concentration, aggregate content, ionic strength, pH, operating pressure/flow rate, temperature, processing duration, total protein load, post-wash protocol, pressure hold duration and cycle frequency. Elevated operating pressure represents a worst-case condition. Pressure release and re-pressurization during processing may compromise viral retention, particularly for parvovirus filtration. Upon pressure suspension, retained viral particles undergo Brownian motion and may permeate larger pores following re-pressurization, leading to viral breakthrough. The occurrence and magnitude of viral leakage depend on solution properties, pressure profile, hold time, virus species, viral titer and membrane type. Scaled-down process models incorporating production-representative pressure cycling must be adopted for viral validation to assess real-world clearance performance.
5 Conclusion
Given the diversity in molecular structure and physicochemical properties of antibody-based biological products, viral inactivation and removal unit operations shall be rationally selected according to product-specific characteristics and customized manufacturing workflows. Systematic characterization of critical process parameters is required to achieve robust viral clearance and inactivation, thereby ensuring the viral safety of commercial antibody therapeutics.
